AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28864226 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDP with Mg
Number of subjects: 0
Study 28864226 — intervention group
Group type: COMPARATOR
Intervention: CDDP alone
Number of subjects: 0
Study 25796986 — intervention group
Group type: EXPERIMENTAL
Intervention: IR/ER HB/APAP
Number of subjects: 403
Study 25796986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 403
Study 23314670 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium infantis natren life start strain super strain (Lifestart 2) (2×10(9) colony‐forming units per capsule) for 3 weeks
Number of subjects: 22
Study 23314670 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 weeks
Number of subjects: 22
Study 20858149 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg three times a day)
Number of subjects: 539
Study 20858149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 539
Study 19947443 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate, a first-line agent for the treatment of postmenopausal osteoporosis.
Number of subjects: 3
Study 17123867 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (intravenous administration)
Number of subjects: 0
Study 17123867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15170026 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg twice a day)
Number of subjects: 16
Study 15170026 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 16
Study 11785999 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler technique measuring myocardial velocities at four left ventricular sites (anterior, left, posterior, septal) and three levels (basal, mid-cavity, apical).
Number of subjects: 60
Study 11785999 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler technique measuring myocardial velocities.
Number of subjects: 60
Study 11785999 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler technique measuring diastolic pulmonary venous flow velocity.
Number of subjects: 60
Study 9433336 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 40 mg/day
Number of subjects: 278
Study 9433336 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/day
Number of subjects: 278
Study 9433336 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 10 mg/day
Number of subjects: 278
Study 9433336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 7663801 — intervention group
Group type: COMPARATOR
Intervention: L-NMMA (490 mg by inhalation)
Number of subjects: 38
Study 7663801 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (30 mg orally for 3 days)
Number of subjects: 38
Study 2698244 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg pindolol
Number of subjects: 46
Study 2698244 — intervention group
Group type: COMPARATOR
Intervention: 3 mg propranolol
Number of subjects: 46
Study 769287 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfacytine (1Gm. per day)
Number of subjects: 132
Study 769287 — intervention group
Group type: COMPARATOR
Intervention: Sulfisoxazole (4Gm. per day)
Number of subjects: 132
Study 769287 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfacytine
Number of subjects: 132
Study 769287 — intervention group
Group type: COMPARATOR
Intervention: Sulfisoxazole
Number of subjects: 132
Study 6264506 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.243% sodium fluoride-silica abrasive dentifrice
Number of subjects: 3093
Study 6264506 — intervention group
Group type: COMPARATOR
Intervention: 0.4% stannous fluoride-calcium pyrophosphate dentifrice
Number of subjects: 3093
Study 6264506 — intervention group
Group type: COMPARATOR
Intervention: Nonfluoride, calcium pyrophosphate abrasive placebo dentifrice
Number of subjects: 3093
Study 29999570 — intervention group
Group type: EXPERIMENTAL
Intervention: Stained CAD/CAM materials (ENA, LVU, CER)
Number of subjects: 15
Study 29999570 — intervention group
Group type: EXPERIMENTAL
Intervention: Polished CAD/CAM materials (CER, LVU, VM2, ENA)
Number of subjects: 15
Study 29999570 — intervention group
Group type: EXPERIMENTAL
Intervention: Stained CAD/CAM materials after 5 years of aging (VM2, ENA, CER, LVU)
Number of subjects: 15
Study 29999570 — intervention group
Group type: EXPERIMENTAL
Intervention: Stained CAD/CAM materials
Number of subjects: 15
Study 29999570 — intervention group
Group type: EXPERIMENTAL
Intervention: Aging effect on CAD/CAM materials (ENA, LVU)
Number of subjects: 15
Study 29999570 — intervention group
Group type: COMPARATOR
Intervention: Feldspathic ceramic (VM2)
Number of subjects: 15
Study 30451047 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administration
Number of subjects: 66
Study 30451047 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face interview
Number of subjects: 66
Study 30451047 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interview
Number of subjects: 66
Study 30451047 — intervention group
Group type: EXPERIMENTAL
Intervention: Postal questionnaire
Number of subjects: 66
Study 27576596 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine mixed with lignocaine 2% with adrenaline 1:80,000 (0.01mg buprenorphine/ml)
Number of subjects: 60
Study 27576596 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 2% with adrenaline 1:80,000 + 0.03mg buprenorphine IM
Number of subjects: 60
Study 27576596 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine 2% with adrenaline 1:80,000 + 1ml saline IM
Number of subjects: 60
Study 24934008 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep processing during study phase
Number of subjects: 0
Study 24934008 — intervention group
Group type: EXPERIMENTAL
Intervention: Different study-test font and orientation
Number of subjects: 0
Study 24934008 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular psychophysiological implicit priming paradigm
Number of subjects: 0
Study 24934008 — intervention group
Group type: COMPARATOR
Intervention: Blood volume pulse change for words at study
Number of subjects: 0
Study 23153715 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation as an add-on therapy for refractory epilepsy
Number of subjects: 0
Study 23153715 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 20338132 — intervention group
Group type: EXPERIMENTAL
Intervention: SFA stent placement
Number of subjects: 1282
Study 20338132 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 1282
Study 20338132 — intervention group
Group type: EXPERIMENTAL
Intervention: SFA stent placement (secondary deployment)
Number of subjects: 1282
Study 20338132 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined primary and secondary SFA stents
Number of subjects: 1282
Study 17103437 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy (1 mg/m²/day) for 2 years
Number of subjects: 25
Study 17103437 — intervention group
Group type: COMPARATOR
Intervention: Growth hormone (GH) therapy (1.5 mg/m²/day) for 1 year after 1 year of observation
Number of subjects: 25
Study 17103437 — intervention group
Group type: COMPARATOR
Intervention: Observation without GH treatment for 1 year
Number of subjects: 25
Study 14688492 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg daily)
Number of subjects: 10355
Study 14688492 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 10355
Study 10670837 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar macrophages from patients with ARDS
Number of subjects: 18
Study 10670837 — intervention group
Group type: COMPARATOR
Intervention: Control patients without lung injury
Number of subjects: 18
Study 9088559 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewer-centered (VC) condition
Number of subjects: 0
Study 9088559 — intervention group
Group type: COMPARATOR
Intervention: Object-centered (OC) condition
Number of subjects: 0
Study 8403822 — intervention group
Group type: EXPERIMENTAL
Intervention: Nottingham Health Profile (NHP)
Number of subjects: 284
Study 8403822 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Limitations Profile (FLP)
Number of subjects: 284
Study 8403822 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Well-being (PWB)
Number of subjects: 284
Study 3777545 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant treatment (heparin for 21 days followed by antivitamin K drugs for 30 days)
Number of subjects: 25
Study 3777545 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hemodilution with 40,000 daltons molecular weight dextran, haematocrit 0.25-0.30, followed by the same anticoagulant treatment as in group I
Number of subjects: 25
Study 3777545 — intervention group
Group type: EXPERIMENTAL
Intervention: Only hemodilution maintained for 21 days
Number of subjects: 25
Study 31326922 — intervention group
Group type: EXPERIMENTAL
Intervention: Supra-acetabular pin insertion
Number of subjects: 50
Study 31629363 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise program led by an accredited exercise physiologist (1 hr × 2 days/week × 12 weeks)
Number of subjects: 24
Study 31629363 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise program led by an accredited exercise physiologist
Number of subjects: 24
Study 31629363 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 24
Study 27866772 — intervention group
Group type: EXPERIMENTAL
Intervention: H1:IC31 vaccination (15μg or 50μg)
Number of subjects: 240
Study 27866772 — intervention group
Group type: EXPERIMENTAL
Intervention: H1:IC31 vaccination (15μg)
Number of subjects: 240
Study 27866772 — intervention group
Group type: EXPERIMENTAL
Intervention: H1:IC31 vaccination of M.tb-uninfected individuals
Number of subjects: 240
Study 27866772 — intervention group
Group type: EXPERIMENTAL
Intervention: H1:IC31 vaccination of M.tb-infected individuals
Number of subjects: 240
Study 26537160 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy only (Group 1)
Number of subjects: 180
Study 26537160 — intervention group
Group type: EXPERIMENTAL
Intervention: Acromioplasty and physiotherapy (Group 2)
Number of subjects: 180
Study 26537160 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotator cuff repair, acromioplasty, and physiotherapy (Group 3)
Number of subjects: 180
Study 26537160 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy only (Group 1) and Acromioplasty and physiotherapy (Group 2)
Number of subjects: 180
Study 26537160 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 180
Study 26537160 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotator cuff repair and acromioplasty
Number of subjects: 180
Study 23370547 — intervention group
Group type: EXPERIMENTAL
Intervention: Grading by site pathologist
Number of subjects: 481
Study 23370547 — intervention group
Group type: EXPERIMENTAL
Intervention: Grading by central pathologist
Number of subjects: 481
Study 23370547 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsies performed early (≤ 6 weeks) after transplant
Number of subjects: 481
Study 23370547 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade A rejection
Number of subjects: 481
Study 23370547 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade B rejection
Number of subjects: 481
Study 22645791 — intervention group
Group type: EXPERIMENTAL
Intervention: Room temperature storage for 24 weeks
Number of subjects: 30
Study 22645791 — intervention group
Group type: EXPERIMENTAL
Intervention: Water storage at 37 degrees C for 24 weeks
Number of subjects: 30
Study 22645791 — intervention group
Group type: EXPERIMENTAL
Intervention: Onda-Cryl resin
Number of subjects: 30
Study 22645791 — intervention group
Group type: EXPERIMENTAL
Intervention: QC-20 resin
Number of subjects: 30
Study 19318694 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 90 mg
Number of subjects: 42
Study 19318694 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 120 mg
Number of subjects: 42
Study 19318694 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg
Number of subjects: 42
Study 17417133 — intervention group
Group type: EXPERIMENTAL
Intervention: Female Condom (FC)
Number of subjects: 0
Study 17417133 — intervention group
Group type: EXPERIMENTAL
Intervention: Male Condom (MC)
Number of subjects: 0
Study 15293426 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract AP
Number of subjects: 33
Study 15293426 — intervention group
Group type: EXPERIMENTAL
Intervention: F2000
Number of subjects: 33
Study 11485110 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin (0.4 ng/kg) injected during sleep
Number of subjects: 20
Study 11485110 — intervention group
Group type: COMPARATOR
Intervention: Placebo injected during sleep
Number of subjects: 20
Study 11485110 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin (0.4 ng/kg) injected during sleep deprivation
Number of subjects: 20
Study 9643595 — intervention group
Group type: EXPERIMENTAL
Intervention: No alteration of anticoagulant treatment (study group)
Number of subjects: 65
Study 9643595 — intervention group
Group type: COMPARATOR
Intervention: Warfarin treatment stopped for 2-3 days (control group)
Number of subjects: 65
Study 7897766 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted uvulopalatoplasty (LAUP)
Number of subjects: 741
Study 7897766 — intervention group
Group type: COMPARATOR
Intervention: Traditional uvulopalatopharyngoplasty (UPPP)
Number of subjects: 741
Study 2958366 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamete intrafallopian transfer (GIFT)
Number of subjects: 0
Study 2958366 — intervention group
Group type: COMPARATOR
Intervention: In vitro fertilization (IVF) and embryo transfer (ET)
Number of subjects: 0
Study 30782352 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Internet-based intervention
Number of subjects: 0
Study 30782352 — intervention group
Group type: COMPARATOR
Intervention: Attention only (control condition)
Number of subjects: 0
Study 27890713 — intervention group
Group type: EXPERIMENTAL
Intervention: Single IV infusion of 20, 100, or 200 × 10^6 human bone marrow-derived mesenchymal stem cells
Number of subjects: 9
Study 27890713 — intervention group
Group type: EXPERIMENTAL
Intervention: Single IV infusion of human mesenchymal stem cells
Number of subjects: 9
Study 25872928 — intervention group
Group type: EXPERIMENTAL
Intervention: DESMOND‐ID programme
Number of subjects: 36
Study 25872928 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 36
Study 23700134 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise bike training with telemonitoring
Number of subjects: 23
Study 21311063 — intervention group
Group type: EXPERIMENTAL
Intervention: New risk model incorporating age, diastolic blood pressure, high-sensitivity C-reactive protein, homocysteine, waist-to-hip ratio, and self-reported health status.
Number of subjects: 4382
Study 21311063 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >85 years
Number of subjects: 4382
Study 21311063 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure <70 mm Hg
Number of subjects: 4382
Study 21311063 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein >3 mg/L
Number of subjects: 4382
Study 21311063 — intervention group
Group type: EXPERIMENTAL
Intervention: Homocysteine >15 umol/L
Number of subjects: 4382
Study 21311063 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist-to-hip ratio >1
Number of subjects: 4382
Study 21311063 — intervention group
Group type: EXPERIMENTAL
Intervention: Fair or poor self-reported health
Number of subjects: 4382
Study 21311063 — intervention group
Group type: COMPARATOR
Intervention: Traditional risk factors (age, smoking)
Number of subjects: 4382
Study 21311063 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall rate of stroke/MI
Number of subjects: 4382
Study 19752338 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 6092
Study 19752338 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 6092
Study 17418554 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 200 microg twice daily + Montelukast 5mg once daily
Number of subjects: 48
Study 17418554 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 200 microg twice daily + Formoterol 9 microg twice daily
Number of subjects: 48
Study 17418554 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg twice daily
Number of subjects: 48
Study 17418554 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 200 microg twice daily + Montelukast 5mg once daily (second month)
Number of subjects: 48
Study 17418554 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 200 microg twice daily + Formoterol 9 microg twice daily (second month)
Number of subjects: 48
Study 17418554 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg twice daily (first and second month)
Number of subjects: 48
Study 15145911 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment to below 140/90 mm Hg
Number of subjects: 0
Study 15145911 — intervention group
Group type: COMPARATOR
Intervention: Control of blood pressure levels
Number of subjects: 0
Study 11304898 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) 1 mg/kg loading infusion over 30 minutes followed by 1 mg/kg/day continuous i.v. infusion
Number of subjects: 20
Study 11304898 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) in ARDS patients
Number of subjects: 20
Study 9789204 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.006 mg/kg apomorphine
Number of subjects: 28
Study 9789204 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.012 mg/kg apomorphine
Number of subjects: 28
Study 9789204 — intervention group
Group type: COMPARATOR
Intervention: Healthy male controls
Number of subjects: 28
Study 7990664 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic fibrosis patients (homozygotes)
Number of subjects: 113
Study 7990664 — intervention group
Group type: EXPERIMENTAL
Intervention: Obligate heterozygotes (parents of CF patients)
Number of subjects: 113
Study 7990664 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 113
Study 2657045 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ritodrine (20 mg every four hours)
Number of subjects: 102
Study 2657045 — intervention group
Group type: COMPARATOR
Intervention: Oral terbutaline (5 mg every four hours)
Number of subjects: 102
Study 29795365 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery-based incentive
Number of subjects: 191
Study 29795365 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct incentive
Number of subjects: 191
Study 29795365 — intervention group
Group type: COMPARATOR
Intervention: Control (daily self‐weighing and text messaging feedback)
Number of subjects: 191
Study 25927849 — intervention group
Group type: EXPERIMENTAL
Intervention: SGJP granules
Number of subjects: 0
Study 25927849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23488491 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine case management
Number of subjects: 1665
Study 23488491 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1665
Study 21609169 — intervention group
Group type: EXPERIMENTAL
Intervention: STI role play simulation teaching
Number of subjects: 0
Study 21609169 — intervention group
Group type: COMPARATOR
Intervention: Control group (no role-play teaching)
Number of subjects: 0
Study 19141661 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly home visits from trained volunteers over a 9‐month period
Number of subjects: 312
Study 19141661 — intervention group
Group type: COMPARATOR
Intervention: Standard professional care only
Number of subjects: 312
Study 16454834 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg-interferon alpha-2b (100 microg/wk) + lamivudine (100 mg/day)
Number of subjects: 266
Study 16454834 — intervention group
Group type: COMPARATOR
Intervention: Peg-interferon alpha-2b (100 microg/wk) + placebo
Number of subjects: 266
Study 15237079 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm-guided treatment (ALGO)
Number of subjects: 0
Study 15237079 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 11244136 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-mm Finn Chamber
Number of subjects: 0
Study 11244136 — intervention group
Group type: EXPERIMENTAL
Intervention: Webril pad
Number of subjects: 0
Study 11244136 — intervention group
Group type: COMPARATOR
Intervention: 8-mm Finn Chamber
Number of subjects: 0
Study 10322844 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuganlin (FGL) oral liquid
Number of subjects: 0
Study 10322844 — intervention group
Group type: COMPARATOR
Intervention: Antipyretic oral liquid (Control)
Number of subjects: 0
Study 2017969 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole-thallium stress testing
Number of subjects: 47
Study 2017969 — intervention group
Group type: COMPARATOR
Intervention: Isometric handgrip exercises added to dipyridamole imaging protocol
Number of subjects: 47
Study 6817658 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled cromoglycate
Number of subjects: 7
Study 6817658 — intervention group
Group type: COMPARATOR
Intervention: No intervention (absence of inhaled cromoglycate)
Number of subjects: 7
Study 31702402 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam 2 mg test tablet (Sanofi‐Aventis de Colombia S.A.)
Number of subjects: 36
Study 31702402 — intervention group
Group type: COMPARATOR
Intervention: Rivotril® (Produtos Roche Químicos e Farmacêuticos S.A.)
Number of subjects: 36
Study 31702402 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations (test and reference)
Number of subjects: 36
Study 29326414 — intervention group
Group type: EXPERIMENTAL
Intervention: Debriefing based on the clinical judgment model
Number of subjects: 48
Study 29326414 — intervention group
Group type: COMPARATOR
Intervention: Usual debriefing
Number of subjects: 48
Study 26342812 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral injection of polyacrylamide hydrogel (Bulkamid) in Group A (previous radiotherapy)
Number of subjects: 46
Study 26342812 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral injection of polyacrylamide hydrogel (Bulkamid) in Group B (no previous radiotherapy)
Number of subjects: 46
Study 23328908 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal cerebellar tDCS
Number of subjects: 21
Study 23328908 — intervention group
Group type: COMPARATOR
Intervention: Sham cerebellar tDCS
Number of subjects: 21